Bevacizumab versus bevacizumab plus lomustine versus lomustine in recurrent glioblastoma.

Recruiting

• Conditions: recurrent glioblastoma; bevacizumab; lomustine

• Registration Number: NL-OMON27373
• Lead Sponsor: Erasmus MC - Daniel den HoedProf. Dr. M.J. van den Bent, MD PhD Neuro-OncologistDrs. W. Taal, MD Neuro-Oncologist

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 144

Inclusion Criteria

1. Age ≥ 18 years;

2. WHO Performance status 0 - 2;

Exclusion Criteria

1. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding;

2. Arterial or venous thrombosis ≤ 12 months prior to registration;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
9 month overall survival (9 mo OS).

Secondary Outcome Measures

Name	Time	Method
1. Objective response rate;<br /><br>2. Median PFS;<br /><br>3. PFS at 6 months and 12 months;<br /><br>4. Median Overall Survival (OS);<br /><br>5. OS at 6 and 12 months;<br /><br>6. Toxicity;<br /><br>7. Neurological deterioration free survival;<br /><br>8. Quality of Life;<br /><br>9. Steroid use.<br /><br>Response will only be assessed in patients with measurable disease.